Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug

Oncogene volume 21, pages 2037–2050 (2002)Cite this article

Abstract

Protein–protein interactions play critical regulatory roles in mediating signal transduction. Previous studies have identified an unconventional, small-molecule, Src signal transduction inhibitor, UCS15A. UCS15A differed from conventional Src-inhibitors in that it did not alter the levels or the tyrosine kinase activity of Src. Our studies suggested that UCS15A exerted its Src-inhibitory effects by a novel mechanism that involved the disruption of protein–protein interactions mediated by Src. In the present study we have examined the ability of UCS15A to disrupt the interaction of Src–SH3 with Sam68, both in vivo and in vitro. This ability of UCS15A was not restricted to Src–SH3 mediated protein–protein interactions, since the drug was capable of disrupting the in vivo interactions of Sam68 with other SH3 domain containing proteins such as Grb2 and PLCγ. In addition, UCS15A was capable of disrupting other typical SH3-mediated protein–protein interactions such as Grb2–Sos1, cortactin–ZO1, as well as atypical SH3-mediated protein–protein interactions such as Grb2–Gab1. However, UCS15A was unable to disrupt the non-SH3-mediated protein–protein interactions of β-catenin, with E-cadherin and α-catenin. In addition, UCS15A had no effect on the SH2-mediated interaction between Grb2 and activated Epidermal Growth Factor receptor. Thus, the ability of UCS15A, to disrupt protein–protein interactions appeared to be restricted to SH3-mediated protein–protein interactions. In this regard, UCS15A represents the first example of a non-peptide, small molecule agent capable of disrupting SH3-mediated protein–protein interactions. In vitro analyses suggested that UCS15A did not bind to the SH3 domain itself but rather may interact directly with the target proline-rich domains.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  • Andreotti AH, Bunnell SC, Feng S, Berg LJ, Schreiber SL . 1997 Nature 385: 93–97

  • Bar-Sagi D, Rotin D, Batzer A, Mandiyan V, Schlessinger J . 1993 Cell 74: 83–91

  • Birge R, Knudsen B, Besser D, Hanafusa H . 1996 Genes to Cells 1: 595–613

  • Cicchetti P, Mayer B, Thiel G, Baltimore D . 1992 Science 257: 803–806

  • Cohen GB, Ren R, Baltimore D . 1995 Cell 80: 237–248

  • Combs A, Kapoor T, Feng S, Chen J, Daude-Snow L, Schreiber S . 1996 J. Am. Chem. Soc. 118: 287–288

  • Dalgarno D, Botfield M, Rickles R . 1997 Biopoly. 43: 383–400

  • Feng S, Kasahara C, Rickles R, Schreiber S . 1995 Proc. Natl. Acad. Sci. 92: 12408–12415

  • Finan P, Hall A, Kellie S . 1996 FEBS. L. 389: 141–144

  • Franz WM, Berger P, Wang JY . 1989 EMBO J. 8: 137–147

  • Fumagalli S, Totty N, Hsuan J, Courtneidge S . 1994 Nature 368: 871–874

  • Fusaki N, Iwanatsu A, Iwashima M, Fujisawa J . 1997 J. Biol. Chem. 272: 6214–6219

  • Gale N, Kaplan S, Lowenstein E, Schlessinger J, Sagi D . 1993 Nature 363: 88–90

  • Gorina S, Pavletich NP . 1996 Science 274: 1001–1005

  • Hanke JH, Gardner JP, Dow RL, Changelian PS, Brisette WH, Weringer EJ, Pollok BA, Connelley PA . 1996 J. Biol. Chem. 271: 695–701

  • Huber A, Weis W . 2001 Cell 105: 391–402

  • Hulsken J, Birchmeier W, Behrens J . 1994 J. Cell Biol. 127: 2061–2069

  • Hunter T . 2000 Cell 100: 113–127

  • Jabado N, Jauliac S, Pallier A, Bernard F, Fischer A, Hivroz X . 1998 J. Immunol. 161: 2798–2803

  • Jackson P, Baltimore D . 1989 EMBO J. 8: 449–456

  • Ji X, Zhang P, Armstrong RN, Gilliland GL . 1992 Biochem. 31: 10169–10184

  • Kato M, Miyazawa K, Kitamura N . 2000 J. Biol. Chem. 275: 37481–37487

  • Katsube T, Takahisa M, Hashimoto N, Kobayashi M, Togashi S . 1998 J. Biol. Chem. 273: 29672–29677

  • Kay BK, Williamson MP, Sudol M . 2000 FASEB J. 14: 231–241

  • Koch C, Anderson D, Moran M, Ellis C, Pawson T . 1991 Science 252: 668–674

  • Ladbury J, Arold S . 2000 Chem. Biol. 7: R3–R8

  • Lewitzky M, Kardinal C, Gehring NH, Schmidt EK, Konkol B, Eulitz M, Birchmeier W, Schaeper U, Feller SM . 2001 Oncogene 20: 1052–1062

  • Li N, Batzer A, Daly R, Yajnik V, Skolnik E, Chardin P, Sagi D, Margolis B, Schlessinger J . 1993 Nature 363: 85–88

  • Lowenstein E, Daly R, Batzer A, Li W, Margolis B, Lammers R, Ullirich A, Schlessinger J . 1992 Cell 70: 431–442

  • Mano H . 1999 Cytokine Growth Factor Rev. 10: 267–280

  • Manser E, Loo TH, Koh CG, Zhao ZS, Chen XQ, Tan L, Tan I, Leung T, Lim L . 1998 Mol. Cell 1: 183–192

  • Mayer B, Baltimore D . 1993 Trends Cell Biol. 3: 8–13

  • Mayer BJ . 2001 J. Cell. Sci. 114: 1253–1263

  • Mayer BJ, Baltimore D . 1994 Mol. Cell Biol. 14: 2883–2894

  • Mongiovi AM, Romano PR, Panni S, Mendoza M, Wong WT, Musacchio A, Cesareni G, Paolo Di Fiore P . 1999 EMBO J. 18: 5300–5309

  • Nguyen J, Porter M, Amoui M, Miller W, Zuckermann R, Lim W . 2000 Chem. Biol. 7: 463–473

  • Nguyen JT, Lim WA . 1997 Nature 4: 256–260

  • Nishida M, Nagata K, Hachimori Y, Horiuchi M, Ogura K, Mandiyan V, Schlessinger J, Inagaki F . 2001 EMBO J. 20: 2995–3007

  • Pai L, Kirkpatrick C, Blanton J, Oda H, Takeichi M, Peifer M . 1996 J. Biol. Chem. 271: 32411–32420

  • Parker MW, Bello ML, Federici G . 1990 J. Mol. Biol. 213: 221–222

  • Pawson T . 1995 Nature 373: 573–580

  • Pawson T, Schlessinger J . 1993 Curr. Biol. 3: 434–442

  • Pillay I, Nakano H, Sharma SV . 1996 Cell Growth Differ. 7: 1487–1499

  • Ponting CP, Aravind L, Schultz J, Bork P, Koonin EV . 1999 J. Mol. Biol. 289: 729–745

  • Reinemer P, Dirr HW, Ladenstein R, Schaffer J, Gallay O, Huber R . 1991 EMBO J. 10: 1997–2005

  • Ren R, Mayer BJ, Cicchetti P, Baltimore D . 1993 Science 259: 1157–1161

  • Richard S, Yu DY, Blumer KJ, Hausladen D, Olszowy MW, Connelly PA, Shaw AS . 1995 Mol. Cell. Biol. 15: 186–197

  • Rickles RJ, Zoller MJ . 1994 EMBO J. 13: 5598–5604

  • Rozakis-Adcock M, Fernley R, Wade J, Pawson T, Bowtell D . 1993 Nature 363: 83–85

  • Rubin GM, Yandell MD, Wortman JR, Gabor Miklos GL, Nelson CR, Hariharan IK, Fortini ME, Li PW, Apweiler R, Fleischmann W, Cherry JM, Henikoff S, Skupski MP, Misra S, Ashburner M, Birney E, Boguski MS, Brody T, Brokstein P, Celniker SE, Chervitz SA, Coates D, Cravchik A, Gabrielian A, Galle RF, Gelbart WM, George RA, Goldstein LS, Gong F, Guan P, Harris NL, Hay BA, Hoskins RA, Li J, Li Z, Hynes RO, Jones SJ, Kuehl PM, Lemaitre B, Littleton JT, Morrison DK, Mungall C, O'Farrell PH, Pickeral OK, Shue C, Vosshall LB, Zhang J, Zhao Q, Zheng XH, Lewis S . 2000 Science 287: 2204–2215

  • Schaeper U, Gehring NH, Fuchs KP, Sachs M, Kempkes B, Birchmeier W . 2000 J. Cell Biol. 149: 1419–1432

  • Schlessinger J . 1994 Curr. Opin. Genet. Dev. 4: 25–30

  • Schwartzberg PL . 1998 Oncogene 17: 1463–1468

  • Seidel-Dugan C, Meyer BE, Thomas SM, Brugge JS . 1992 Mol. Cell. Biol. 12: 1835–1845

  • Sharma SV, Oneyama C, Yamashita Y, Nakano H, Sugawara K, Hamada M, Kosaka N, Tamaoki T . 2001 Oncogene 20: 2068–2079

  • Shen Z, Batzer A, Koehler JA, Polakis PP, Schlessinger J, Lydon NB, Moran MF . 1999 Oncogene 18: 4647–4653

  • Smithgall T . 1995 J. Pharmacol Toxicol Methods 34: 125–132

  • Sparks A, Quilliam L, Thorn J, Der C, Kay B . 1994 J. Biol. Chem. 269: 23853–23856

  • Sparks AB, Rider JE, Hoffman NG, Fowlkes DM, Quilliam LA, Kay BK . 1996 Proc. Natl. Acad. Sci. USA 93: 1540–1544

  • Sudol M . 1998 Oncogene 17: 1469–1474

  • Summy J, Guappone A, Sudol M, Flynn D . 2000 Oncogene 19: 155–160

  • Taylor S, Anafi M, Pawson T, Shalloway D . 1995 J. Biol. Chem. 270: 10120–10124

  • Taylor SJ, Shalloway D . 1994 Nature 368: 867–871

  • Tsukita S, Furuse M, Itoh M . 1999 Curr. Opin. Cell Biol. 11: 628–633

  • Yamashita Y, Miyazato A, Ohya K, Ikeda U, Shimada K, Miura Y, Ozawa K, Mano H . 1996 Jpn. J. Cancer Res. 87: 1106–1110

  • Yu H, Chen J, Feng S, Dalgarno D, Brauer A, Schreiber S . 1994 Cell 76: 933–945

  • Zhu T, Goh ELK, LeRoith D, Lobie PE . 1998 J. Biol. Chem. 273: 33864–33875

Download references

Acknowledgements

We thank Dr Margaret Quinlan for carefully editing the manuscript and for her valuable comments.

Author information

Authors and Affiliations

  1. Tokyo Research Laboratories, Kyowa Hakko Kogyo Co., Ltd 3-6-6 Asahi-cho, Machida-shi, Tokyo, 194, Japan

    Chitose Oneyama, Hirofumi Nakano & Sreenath V Sharma

Authors
  1. Chitose Oneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hirofumi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sreenath V Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sreenath V Sharma.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oneyama, C., Nakano, H. & Sharma, S. UCS15A, a novel small molecule, SH3 domain-mediated protein–protein interaction blocking drug. Oncogene 21, 2037–2050 (2002). https://doi.org/10.1038/sj.onc.1205271

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205271

Keywords

This article is cited by

Search

Advanced search

Quick links